Optimization of Individual and Population Designs Using Splus

We address the problem of design optimization for individual and population pharmacokinetic studies. We develop Splus generic functions for pharmacokinetic design optimization: IFIM, a function for individual design optimization similar to the ADAPT II software, and PFIM_OPT, a function for population design optimization which is an extension of the Splus function PFIM for population design evaluation. Both evaluate and optimise designs using the Simplex algorithm. IFIM optimizes the sampling times in continuous intervals of times; PFIM_OPT optimizes either, for a given group structure of the population design, only the sampling times taken in some given continuous intervals or, both the sampling times and the group structure, performing then statistical optimization. A combined variance error model can be supplied with the possibility to include parameters of the error model as parameters to be estimated. The performance of the optimization with the Simplex algorithm is demonstrated with two pharmacokinetic examples: by comparison of the optimized designs to those of the ADAPT II software for IFIM, and to those obtained using a grid search or the Fedorov–Wynn algorithm for PFIM_OPT. The influence of the variance error model on design optimization was investigated. For a given total number of samples, different group structures of a population design are compared, showing their influence on the population design efficiency. The functions IFIM and PFIM_OPT offer new efficient solutions for the increasingly important task of optimization of individual or population pharmacokinetic designs.

[1]  William H. Press,et al.  Numerical Recipes in Fortran 77: The Art of Scientific Computing 2nd Editionn - Volume 1 of Fortran Numerical Recipes , 1992 .

[2]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[3]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[4]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[6]  Andrew C. Hooker,et al.  An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations , 2004, Annals of Biomedical Engineering.

[7]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[8]  Michel Tod,et al.  Impact of Pharmacokinetic–Pharmacodynamic Model Linearization on the Accuracy of Population Information Matrix and Optimal Design , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[10]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[11]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[12]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[13]  Jenny Wang,et al.  A computationally efficient approach for the design of population pharmacokinetic studies , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  France Mentré,et al.  Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[15]  L Aarons,et al.  Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.

[16]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[17]  France Mentré,et al.  Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  Jon Wakefield,et al.  Population modelling in drug development , 1999, Statistical methods in medical research.

[20]  Stephen B. Duffull,et al.  The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..

[21]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.